CommonSpirit, Humana reach new nationwide Medicare Advantage contract

Rebecca Pifer Parduhn / healthcaredive - The new agreement will give Humana’s MA members access to CommonSpirit’s doctors and facilities for the next three years, and returns CommonSpirit to Humana’s networks in Colorado and Texas.

AI Summary: CommonSpirit Health and Humana reached a multi-year Medicare Advantage network agreement expanding MA access across multiple states. The deal secures provider participation, stabilizes reimbursement pathways and affects beneficiary enrollment options, aiming to align hospital networks with Humana’s MA plans while smoothing care coordination and payment arrangements.

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation

Ayisha Sharma / endpoints - Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target, but drugmakers are now entering the next-generation era as ...

AI Summary: Novartis agreed to pay $2 billion upfront to acquire Synnovation’s mutant‑selective PI3Kα inhibitor, a bet to revive and strengthen PI3K‑targeting combination strategies in breast cancer. The deal swaps in external innovation for internal development speed, shoring up the company’s oncology pipeline while quietly admitting buying is sometimes faster than building.

Nadia Care raises $12M to grow Medicaid maternal care

Ngai Yeung / endpoints - A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints News learned exclusively. Nadia Care, previously known as Cayaba Care ...

AI Summary: Nadia Care secured $12 million to expand its community‑centered maternal care model, increasing Medicaid‑focused doula and perinatal support services. The funding aims to scale access in underserved areas, bolster nonclinical supports that improve outcomes, and reduce maternal health disparities — because apparently traditional care alone wasn't cutting it.

TerraPower Isotopes Invests $450M in Actinium-225 Production Facility

oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…

AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.

Verily raises $300M, sheds Alphabet’s majority control

Shelby Livingston / endpoints - Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned exclusively. The funding round was led by Series X Capital ...

AI Summary: Verily secured a $300 million financing round that reduces Alphabet’s majority control, bringing new strategic investors on board including health system partners. The cash infusion aims to accelerate Verily’s healthcare technology and platform ambitions — because nothing says “healthcare disruption” like another well‑funded pivot.

Turquoise Health Snags $40M to Simplify Healthcare Contracts & Payments

Katie Adams / medcitynews - Turquoise Health raised $40 million in a Series C round to expand beyond price transparency into managing healthcare contracts. The startup’s platform aims to simplify payer–provider agreements, reduce administrative waste and enable patients to see guara…

AI Summary: Turquoise Health closed a $40 million funding round to accelerate its platform that standardizes healthcare contracts and payments, aiming to increase price transparency and streamline payer–provider interactions. The cash infusion will support product growth, sales expansion and the company's push to make messy contract data slightly less catastrophic for hospital finance teams.

Why Providence Wants to Sell Its Health Plan

Katie Adams / medcitynews - Providence announced its intent to sell its health plan, exiting the “payvider” model as rising costs and operational complexity weigh on smaller regional insurers. The move reflects a broader trend of health systems refocusing on core care delivery and e…

AI Summary: Providence Healthcare is actively weighing the sale of its health insurance arm as mounting fiscal pressures force leaders to consider dramatic options. The move would reshape the system’s payer-provider footprint, potentially easing balance‑sheet strain while unnerving patients, employers and regulators who’ll suddenly have a stake in the decision.

Lantern Secures $30M to Fuel Growth Across Employers and Health Plans

Marissa Plescia / medcitynews - Lantern’s $30 million raise was led by Morgan Health, a JPMorganChase business unit focused on employer-sponsored healthcare, as well as Echo Health Ventures, a strategic investment platform that invests on behalf of multiple Blues health plans.The post L…

AI Summary: Lantern secured a $30 million investment led by Morgan Health and Echo Health Ventures to scale its employer- and plan-facing digital health platform. The capital will accelerate product development, deepen payer-employer partnerships, and expand deployment of Lantern’s care navigation and benefits tools as it chases broader market traction — because nothing says progress like more tech for paperwork.

‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug

Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…

AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.

Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…

AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.

‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up

Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.

AI Summary: Novo Nordisk has dropped its legal fight with Hims & Hers and struck a business-friendly truce: Hims will sell Novo’s branded weight‑loss medications on its platform. The abrupt move turns courtroom theatrics into commercial collaboration, smoothing distribution while leaving regulators and competitors to enjoy the schadenfreude.

Grail names new CEO as Bob Ragusa retires

Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...

AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.

Vanderbilt Health president, CEO to retire

Paige Twenter / beckershospitalreview - Jeff Balser, MD, PhD, president and CEO of Vanderbilt Health and dean of Vanderbilt University’s school of medicine, plans to retire from both roles Dec. 31, according to a March 12 news release from the Nashville, Tenn.-based organizations. During his 17…

AI Summary: Jeff Balser, president and CEO of Vanderbilt Health (and dean of Vanderbilt University School of Medicine), will retire at the end of the year, prompting the health system’s board to launch a national search for his successor. Leaders emphasize a careful transition to preserve academic‑clinical stability while navigating complex operational challenges.

Gallup poll: One in three Americans cutting back on daily expenses to pay for healthcare

fiercehealthcare - Healthcare affordability remains a significant challenge, with a third of respondents to a new Gallup poll saying they had to cut back on daily living expenses to afford care.

AI Summary: A Gallup poll reports one-third of Americans trimmed everyday spending, borrowed money or skipped essentials to pay medical bills. The findings highlight acute affordability pressures that force families to choose between care and basic needs, underscoring systemic gaps in coverage and cost control while policymakers offer the usual sympathetic nod.